Rothschild Investment LLC Has $7.03 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

Rothschild Investment LLC trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 9.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 293,301 shares of the company's stock after selling 28,901 shares during the period. Rothschild Investment LLC's holdings in Kenvue were worth $7,033,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of KVUE. LaFleur & Godfrey LLC raised its position in Kenvue by 29.8% during the fourth quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock valued at $1,736,000 after buying an additional 18,650 shares during the period. Geneos Wealth Management Inc. acquired a new position in Kenvue during the fourth quarter valued at $29,000. Perigon Wealth Management LLC raised its position in Kenvue by 19.8% during the fourth quarter. Perigon Wealth Management LLC now owns 19,249 shares of the company's stock valued at $408,000 after buying an additional 3,187 shares during the period. Swedbank AB raised its position in Kenvue by 13.1% during the fourth quarter. Swedbank AB now owns 890,980 shares of the company's stock valued at $19,022,000 after buying an additional 103,117 shares during the period. Finally, OLD National Bancorp IN raised its position in Kenvue by 14.6% during the fourth quarter. OLD National Bancorp IN now owns 22,971 shares of the company's stock valued at $490,000 after buying an additional 2,927 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Down 1.2%

KVUE stock traded down $0.27 during mid-day trading on Wednesday, hitting $21.94. The stock had a trading volume of 9,323,616 shares, compared to its average volume of 16,398,353. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $42.10 billion, a price-to-earnings ratio of 41.40, a PEG ratio of 2.62 and a beta of 1.02. The company has a fifty day moving average of $23.25 and a 200 day moving average of $22.62. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The firm's revenue for the quarter was down 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.28 EPS. On average, equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were issued a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.74%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price target on the stock. Canaccord Genuity Group upped their price target on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Barclays upped their price target on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Piper Sandler upped their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Finally, Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.